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Breast cancer with bone metastasis is essentially incurable with current anticancer 
therapies. The bone morphogenetic protein (BMP) pathway is an attractive therapeutic 
candidate, as it is involved in the bone turnover and in cancer cell formation and 
their colonization of distant organs such as the bone. We previously reported that in 
breast cancer cells, the ZNF217 oncogene drives BMP pathway activation, increases 
the metastatic growth rate in the bone, and accelerates the development of severe 
osteolytic lesions in mice. In the present study, we aimed at investigating the impact of 
the LDN-193189 compound, a potent inhibitor of the BMP type I receptor, on metastasis 
development in vivo. ZNF217-revLuc cells were injected into the left ventricle of nude mice 
(n = 16) while control mice (n = 13) were inoculated with control pcDNA6-revLuc cells. 
Mice from each group were treated or not with LDN-193189 for 35 days. We found that 
systemic LDN-193189 treatment of mice significantly enhanced metastasis development, 
by increasing both the number and the size of metastases. In pcDNA6-revLuc-injected 
mice, LDN-193189 also affected the kinetics of metastasis emergence. Altogether, 
these data suggest that in vivo, LDN-193189 might affect the interaction between breast 
cancer cells and the bone environment, favoring the emergence and development of 
multiple metastases. Hence, our report highlights the importance of the choice of drugs 
and therapeutic strategies used in the management of bone metastases.
Keywords: breast cancer, ZNF217, bone metastasis, bone morphogenetic protein pathway inhibitor, LDN-193189
INTRODUCTION
Breast cancer is the most frequent cancer among women (Ferlay et al., 2015). More than two-
thirds of breast cancer patients are expected to die after the development of bone metastases (BM), 
primarily osteolytic lesions (Coleman, 2006). Breast cancers with BM are currently mostly incurable; 
therefore, the identification of suitable therapeutic candidates is of utmost importance.
Abbreviations: BM, bone metastases; BMP, Bone Morphogenetic Protein; IP, intra-peritoneal
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Previous data strongly suggest that the bone morphogenetic 
protein (BMP) pathway, a critical regulator of bone homeostasis, 
may be a promising therapeutic target in tumorigenesis and 
BM (Bach et al., 2018). Indeed, this pathway is involved in cell-
autonomous functions in tumor cells, as well as tumor–stroma 
interactions in the bone environment (Keller et al., 2001; Barnes 
et al., 2004; Javed et al., 2005; Alarmo and Kallioniemi, 2010; 
Sethi and Kang, 2011). The BMP pathway has been ascribed 
both tumor-promoting or -suppressing activities, according to 
the context (Bach et al., 2018), though its activation is mainly 
associated with tumor progression and metastasis development. 
For instance, in human breast cancer cells, BMP-Smad signaling 
stimulates development of BM (Katsuno et al., 2008). BMP 
inhibitors (Jiramongkolchai et al., 2016) thus constitute a 
promising approach for managing tumorigenesis and breast 
cancer-derived BM.
We previously reported that ectopic expression of the ZNF217 
oncogene in MDA-MB-231 breast cancer cells leads to the 
constitutive activation of the BMP pathway, indicating that ZNF217 
is a novel upstream BMP signaling activator (Bellanger et al., 
2017). A series of in vitro experiments showed that BMP signaling 
is strongly involved in ZNF217-mediated breast cancer cell 
aggressiveness. Indeed, treatment of MDA-MB-231 breast cancer 
cells overexpressing ZNF217 with specific BMP inhibitors (one of 
which being LDN-193189) led to impaired ZNF217-dependent 
cell migration and cell invasion and impeded chemotaxis to the 
bone (Bellanger et al., 2017). In mice, experiments conducted 
by intracardiac injection of ZNF217-positive breast cancer cells 
revealed that these latter rapidly colonize the bone, leading to the 
development of severe multiple BM detectable as early as 7 days 
post-injection (Bellanger et al., 2017). In this well-described and 
well-characterized in vivo model, mice injected with ZNF217-
positive breast cancer cells developed osteolytic lesions validated 
by microCT, and only in extremely rare cases were concomitant 
metastases at other locations observed (Bellanger et al., 2017). 
This novel in vivo model of BM thus represents an attractive 
model for testing candidate drugs.
LDN-193189 is a potent inhibitor of the BMP type I receptor 
(Cuny et al., 2008) and was chosen in our study as its efficacy 
and toxicity in mice are well characterized (Yu et al., 2008; 
Boergermann et al., 2010; Lee et al., 2011; Balboni et al., 2013). 
Furthermore, among the different BMP inhibitors, LDN-
193189 has scarcely been tested in the prevention of metastasis 
development. To our knowledge, only one in vivo study reported 
that LDN-193189 prevents prostate tumor growth rate in the 
bone and development of osteoblastic lesions (Lee et al., 2011). 
Based on our novel in vivo murine model of osteolytic lesions 
(Bellanger et al., 2017), we aimed at investigating whether 
systemic inhibition of the BMP pathway by LDN-193189 could 
influence metastasis development.
MATERIALS AND METHODS
Cell Culture and Treatments
MDA-MB-231-pcDNA6, MDA-MB-231-ZNF217, and their stable 
luciferase-transfected derived cell lines pcDNA6-revLuc and 
ZNF217-revLuc were previously established and described (Thollet 
et al., 2010; Vendrell et al., 2012). We previously validated in our cell 
lines the inhibitory action of 10−7 M LDN-193189 (Sigma, France) 
on the BMP pathway (Bellanger et al., 2017). Before injection into 
mice, pcDNA6-revLuc and ZNF217-revLuc cells were treated for 
4 h with 10−7 M of LDN-193189 or vehicle (distilled water).
Animal Models
Experiments were conducted following the European Union 
guidelines and approved by the ethics committee of Grenoble, 
France (C2EA-12 ComEth Grenoble). As previously described 
(Bellanger et al., 2017), pcDNA6-revLuc or ZNF217-revLuc cells 
(2.5 × 105) were injected into the cardiac left ventricle of n = 18 
or n = 20 6-week-old athymic NMRI nude female mice (Janvier 
Labs, France), respectively. Cell implantation was immediately 
controlled by in vivo bioluminescence imaging (IVIS Kinetic, 
PerkinElmer). Only mice, the bioluminescent signal of which 
was diffused throughout the whole body, were considered to be 
correctly implanted (13/18 and 16/20, respectively, Supplementary 
Figure 1A) and were included in the following experimental groups: 
pcDNA6-revLuc (n = 5), pcDNA6-revLuc + LDN-193189 (n = 8), 
ZNF217-revLuc (n = 8), and ZNF217-revLuc + LDN-193189 
(n = 8). Subsequently, from day 0 to day 35, pcDNA6-revLuc mice 
or ZNF217-revLuc mice received daily intra-peritoneal (IP) 
injections of LDN-193189 (3 mg/kg body weight in distilled 
water) or vehicle (distilled water). The LDN-193189 experimental 
setup was based on previous in vivo studies (Yu et al., 2008; Lee 
et al., 2011; Balboni et al., 2013). LDN-193189-treated mice did 
not exhibit any loss in their body weight, demonstrating that the 
inhibitor had no severe toxic side effects. Bioluminescence imaging 
(IVIS Kinetic, Caliper), was performed weekly as previously 
described (Bellanger et al., 2017). A p value of <0.05 was considered 
statistically significant (Mann–Whitney, StatView™ Software).
Whole-Body Bioluminescence and X-Ray 
Microtomography (microCT) Imaging
Five minutes before imaging, vigil mice received an IP injection 
of 150 µg/g of D-luciferin (Promega) and were then anesthetized 
(isoflurane 4% for induction and 1.5% thereafter) and placed in the 
IVIS Kinetic imaging system (PerkinElmer). MicroCT was then 
performed using the vivaCT40 (ScancoMedical) at 45 keV with 
a 177-mA intensity, a 200-ms integration time, and an 80-mm 
isotropic voxel size.
Histology
Hind limbs and spines from animals were fixed, decalcified in 
16% EDTA, and embedded in paraffin. Five-micrometer tissue 
sections were stained with Goldner’s Trichrome and processed 
for histological analysis.
RESULTS
Figure 1A and B illustrates the kinetics and amplitude of 
metastasis development in mice implanted with pcDNA6-revLuc 
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FIGURE 1 | Kinetics and development of metastases in vivo. The kinetics of metastases development were followed by bioluminescence in mice injected with 
(A) ZNF217-revLuc cells or (B) pcDNA6-revLuc cells, and treated or not with LDN-193189 (representation of one mouse per group representative of the entire 
group). (C) Whole-body bioluminescence and microCT imaging between 35 and 42 days after intracardiac injection of ZNF217-revLuc cells. (D) Representative 
bioluminescence image of an entire mouse exhibiting multiple metastasis foci including an osteolytic BM detected by microCT scan at the left tibia and by histological 
examination both at the vertebrae and the tibia from bone tissue sections stained with Goldner’s trichrome. Mineralized bone is stained in green and cells are stained in dark 
red. White stars identify metastasis foci. Histological examination of similar areas from a metastasis-free mouse is also shown in vertebrae and tibia. Scale bars: 100 μm.
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or ZNF217-revLuc cells, treated or not with LDN-193189. The 
pattern of metastases distribution observed in ZNF217-revLuc 
cell-injected mice, treated or not with LDN-193189, was totally 
superimposed with those previously observed in our well-
characterized in vivo model of osteolytic lesions (Bellanger 
et al., 2017) (Supplementary Figure 1B). MicroCT images are 
capable of highlighting osteolytic lesions following a longer 
bone remodeling period, i.e., once the cells had sufficiently 
colonized the tissue (Sanches et al., 2015). Figure 1C illustrates 
representative microCT images, highlighting osteolytic bone 
lesions following intracardiac injection of ZNF217-revLuc cells. 
Histological investigations validated osteolytic lesions and the 
presence of breast metastatic tumor cells inside and in close 
contact with bone (Figure 1D).
Intracardiac injection of ZNF217-revLuc cells into mice (n = 
16) led to the rapid development of multiple bioluminescent 
metastases (Figure 2A). After 7 and 21 days post-injection, 
38% and 100% of the untreated injected mice (n = 8) developed 
metastases, respectively, corroborating our previous observation 
(Bellanger et al., 2017). In the group of ZNF217-revLuc-injected 
mice treated with LDN-193189 (n = 8), the kinetics of metastasis 
development was very rapid, similarly to that observed in the 
ZNF217-revLuc-injected mice (n = 8) (Figure 2A). Strikingly, 
the total metastases load and the average number of metastases 
per mouse were higher in the LDN-193189-treated group 
compared to the non-treated group, and this increase reached 
significance (P = 0.017) at days 28 and 35 post-implantation 
(Figure 2B and C).
All ZNF217-revLuc-injected mice developed multiple 
metastases, but those who were treated with LDN-193189 
displayed much more metastases per mouse compared to the 
non-treated group (11.0 ± 5.0 vs. 6.1 ± 2.5) at 28 days post-
injection (Figure 2C). Furthermore, the average bioluminescent 
signal per metastasis tended to be higher in the LDN-193189-
treated group compared to the non-treated group, suggesting 
that in the presence of this BMP inhibitor, individual metastases 
are larger (Figure 2D).
Unlike ZNF217-revLuc-injected mice, and consistent 
with our previous report (Bellanger et al., 2017), only 1 out 
of 5 non-treated pcDNA6-revLuc-injected mice developed 
a single metastasis, detectable only at 35 days post-injection 
(Figure 2E). The LDN-193189 treatment of pcDNA6-revLuc-
injected mice (n = 8) affected both the incidence of metastases 
development (Figure 2E), the total metastases load (Figure 
2F), and the average number of metastases per mouse (Figure 
2G). Indeed, 50% of LDN-193189-treated pcDNA6-revLuc-
injected mice (4 of 8 mice) developed one to four metastases 
detectable as early as day 28 post-injection, while none were 
detectable in the non-treated group (Figure 2E). Additionally, 
the bioluminescent signal observed in the LDN-193189-treated 
pcDNA6-revLuc-injected group, though weaker than ZNF217-
induced metastases, was significantly higher than that in the 
non-treated group at day 35 post-injection (Figure 2F, P = 
0.029). Figure 2H illustrates and summarizes the number of 
bioluminescent metastases in mice injected with pcDNA6-
revLuc or ZNF217-revLuc cells, and treated or not with 
LDN-193189.
DISCUSSION
Therapeutic BM strategies aiming at targeting the BMP pathway 
are very attractive, firstly because the latter is involved in the 
physiology and pathology of bone turnover (Rosen, 2006) and 
secondly because it might be dysregulated in cancer cells leading 
to metastases, in particular to the bone (Katsuno et al., 2008). 
Previous studies reported that i) the DMH1 BMP inhibitor 
prevents tumor burden in breast cancer and lung metastatic 
growth (Owens et al., 2015); ii) halofuginone, a dual BMP and 
TGFβ inhibitor, reduces breast cancer osteolytic lesions (Juarez 
et al., 2017); and iii) the BMP antagonist noggin prevents 
development of osteolytic lesions of prostate cancer cells (Feeley 
et al., 2006).
However, the BMP pathway has paradoxical effects in 
tumorigenesis and metastasis development, owing possibly to 
the fine balance between members belonging to this pathway, or 
between BMP signaling and other pathways, in specific cellular 
contexts or genetic backgrounds (Jiramongkolchai et  al., 2016; 
Bach et al., 2018). Such complexity is highlighted by apparently 
conflicting data using BMP inhibitors. Indeed, the BMP antagonist 
noggin has also been described to contribute to the development 
of osteolytic BM (Secondini et al., 2011). Moreover, LDN-
193189, while inducing decreased tumor burden of colorectal 
cancer cells (Yokoyama et al., 2017), preventing the growth of 
pancreatic or breast cancer cells in vivo, and increasing survival 
of mice with ovarian cancer (Lee et al., 2011; Balboni et al., 2013; 
Ali et al., 2015), was also shown to increase the risk of intestinal 
carcinogenesis (Whissell et al., 2014).
Using a well-described in vivo model of BM metastases 
in breast cancer (Bellanger et al., 2017), the present report 
originally investigates the impact of LDN-193189 on metastasis 
development. Our unexpected and major finding is that systemic 
treatment with the LDN-193189 molecule has a pro-metastatic 
effect and stimulates the development of metastases, both in 
pcDNA6-revLuc-injected mice and in ZNF217-revLuc-injected 
mice. The impact was significantly greater with ZNF217-positive 
breast cancer cells displaying aggressiveness and with the ability 
to develop severe osteolytic lesions. This unexpected result might 
reflect the impact of this BMP inhibitor on the soil (the bone 
microenvironment) and/or on the seed (MDA-MB-231 breast 
cancer cells). Consistently, previous studies suggested that LDN-
193189 facilitates bone resorption, represses bone formation, or 
reduces heterotopic ossification (Yu et al., 2008; Lee et al., 2011; 
Inubushi et al., 2017). Alternatively, LDN-193189 treatment 
may induce in both control and ZNF217-postive MDA-MB-231 
cells yet uncharacterized molecular events favoring their in 
vivo interaction with the bone environment for osteolytic BM 
development. Consistently, LDN-193189 displays BMP signaling 
inhibitory activities on both ZNF217-overexpressing cells and 
control cells, suggesting that this compound is able to block the 
activation of both ZNF217-dependent and -independent BMP 
signaling (Bellanger et al., 2017). Regardless of the context, 
LDN-193189 treatment seems to accelerate BM development, 
independently of the level of activation of BMP signaling in 
breast cancer cells. The concomitant development of metastases 
to locations other than bone is very rarely obtained in the in vivo 
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model used in this study (Bellanger et al., 2017). However, future 
work investigating whether LDN-193189 treatment impacts 
metastases development other than in the BM is much needed. 
Finally, one cannot preclude possible off-target effects of LDN-
193189, destabilizing the balance between this pathway and 
other signaling pathways in the environment or in breast cancer 
cells (Yu et al., 2008; Vogt et al., 2011).
In conclusion, using an in vivo model of breast cancer BM, 
we found that the LDN-193189 BMP inhibitor displays pro-
metastatic properties. Although this study does not refute the 
use of BMP inhibitors in oncology and in the prevention of 
metastases, it highlights the necessity to gain further insight into 
the fine balance governed by the BMP signaling pathway between 
tumor cells and the environment to improve the development of 
future drugs.
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FIGURE S1 | (A) Bioluminescence imaging performed immediately after 
intracardiac injection of cells expressing luciferase for validation of mice included 
in the experiments. (B) Distribution pattern of the bioluminescent metastases 
detected in the ZNF217-revLuc injected mice treated with LDN-193189 and 
ZNF217-revLuc injected mice treated with vehicle.
FIGURE 2 | The LDN-193189 BMP inhibitor enhances metastases development in vivo. ZNF217-revLuc or pcDNA6-revLuc cells were delivered via intracardiac 
injection into the bloodstream of nude mice. (A) Kaplan–Meier analysis of metastasis-free mice in LDN-193189-treated (n = 8) and non-treated (n = 8) 
ZNF217-revLuc-injected mice. (B) Total metastases load measured by in vivo bioluminescence imaging in LDN-193189-treated (n = 8) and non-treated (n = 8) 
ZNF217-revLuc-injected mice. (C) Average number of metastases per ZNF217-revLuc-injected mouse. (D) Total bioluminescent signal per metastasis in LDN-
193189-treated and non-treated ZNF217-revLuc-injected mice. (E) Kaplan–Meier analysis of metastasis-free mice in LDN-193189-treated (n = 8) and non-treated 
(n = 5) pcDNA6-revLuc-injected mice. (F) Total metastases load measured by in vivo bioluminescence imaging in LDN-193189-treated (n = 8) and non-treated 
(n = 5) pcDNA6-revLuc-injected mice. (G) Average number of metastases per pcDNA6-revLuc-injected mouse. Results are presented as mean ± standard error of 
the mean (SEM) in (B), (C), (D), (F), and (G). *P < 0.05 (Mann–Whitney test). (H) Distribution of the number of metastases developed by each group of mice.
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